IP Library Granted Patent US 9,926,537
Granted Patent B2
US 9,926,537 · App. 15/649,462 · Granted Mar 27, 2018

Variant forms of urate oxidase and use thereof

Inventors: Jacob Hartman (Holon, IL); Simona Mendelovitz (Ramat Aviv, IL)
Assignee: Horizon Pharma Rheumatology LLC
C12N9/0048A61K38/44A61K47/60C12N9/0046C12Y107/03003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,926,537
App. No.
15/649,462
Granted
Mar 27, 2018
Kind
B2
Abstract

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Claims (29)

1. A nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 8.

2. The nucleic acid molecule of claim 1 , comprising the polynucleotide sequence of SEQ ID NO: 10.

3. The nucleic acid molecule of claim 1 , wherein the polynucleotide sequence is operatively linked to an osmB promoter.

4. A nucleic acid vector comprising the nucleic acid molecule of claim 1 .

5. A host cell comprising the nucleic acid vector of claim 4 .

6. The host cell of claim 5 , wherein the host cell is an Escherichia coli ( E. coli ).

7. An E. coli comprising a nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 8.

8. The E. coli of claim 7 , comprising the polynucleotide sequence of SEQ ID NO: 10.

9. The E. coli of claim 7 , wherein the polynucleotide sequence is operatively linked to an osmB promoter.

10. A method for producing a polypeptide comprising:

(i) culturing an E. coli comprising a nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 8, under conditions such that the polynucleotide sequence is expressed by the host cell; and

(ii) isolating the expressed polypeptide.

11. The method of claim 10 , comprising the polynucleotide sequence of SEQ ID NO: 10.

12. The method of claim 10 , wherein the polynucleotide sequence is operatively linked to an osmB promoter.

13. The method of claim 10 , further comprising conjugating the isolated polypeptide to polyethylene glycol (PEG).

14. The method of claim 13 , wherein the PEG is monomethoxyPEG (mPEG).

15. The method of claim 14 , wherein the mPEG has a molecular weight between 5 kDa and 20 kDa.

16. The method of claim 15 , wherein the mPEG has a molecular weight of about 10 kDa.

17. The method of claim 16 , wherein the mPEG is covalently attached to a lysine residue of the uricase.

18. The method of claim 16 , comprising about 2-12 mPEG molecules per polypeptide.

19. A method for producing a conjugate comprising a polypeptide and PEG comprising:

(i) providing a polypeptide comprising the amino acid sequence of SEQ ID NO: 8; and

(ii) conjugating the polypeptide to polyethylene glycol (PEG).

20. The method of claim 19 , wherein the PEG is monomethoxyPEG (mPEG).

21. The method of claim 20 , wherein the mPEG has a molecular weight between 5 kDa and 20 kDa.

22. The method of claim 21 , wherein the mPEG has a molecular weight of about 10 kDa.

23. The method of claim 22 , wherein the mPEG is covalently attached to a lysine residue of the polypeptide.

24. The method of claim 23 , wherein the conjugate comprises about 2-12 mPEG molecules per polypeptide.

25. The method of claim 24 , wherein the conjugate is prepared with monomethoxy-poly(ethylene glycol)-nitrophenyl carbonate.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0075 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 061805 FRAME 0076. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 1, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 062073/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC
Reel/Frame 061805/0076 →
SECURITY AGREEMENT Recorded Oct 24, 2018
From: HORIZON PHARMA RHEUMATOLOGY LLC; HZNP LIMITED; HORIZON THERAPEUTICS, LLC
To: CITIBANK, N.A.
Reel/Frame 047720/0068 →
CHANGE OF NAME Recorded Feb 8, 2018
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 045286/0014 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: HARTMAN, JACOB; MENDELOVITZ, SIMONA
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 044868/0085 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, LLC
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 045285/0901 →
CHANGE OF NAME Recorded Feb 8, 2018
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 045285/0927 →
Continuity (7)
Division 15490736 · Apr 18, 2017
Continuation 14671246 · Mar 27, 2015
Continuation 13972167 · Aug 21, 2013
Continuation 13461170 · May 1, 2012
Division 11918297
Provisional Application 60670573 · Apr 11, 2005
Related Publication 20170321193A1 · Nov 9, 2017